Oremek G M, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel K H
Klinikum der Johann-Wolfgang Goethe-Universität Frankfurt, Germany.
Anticancer Res. 1999 Jul-Aug;19(4A):2599-601.
Various isoforms of the glycolytic enzyme pyruvate kinase are expressed in different cell-types. One of these isoforms, the type Tu M2-PK, is strongly overexpressed by tumor cells and released into body fluids. The concentration of Tu M2-PK in body fluids can be quantitatively determined by a commercially available enzyme-linked immunosorbent assay (ELISA)-kit. Using this kit, the Tu M2-PK concentration was measured in EDTA-plasma of 64 patients with renal carcinoma and 10 patients suffering from nephritis. The ranges of the Tu M2-PK-concentrations of the two groups did not overlap, indicating a highly significant discrimination of renal carcinoma and benign renal diseases. Furthermore, the Tu M2-PK-concentration in EDTA-plasma correlates strongly with the Robson tumor stage of the 64 patients. The present results indicate that the Tu M2-PK might be the first tumor marker which could be an excellent complementation of the diagnostic program for renal carcinoma.
糖酵解酶丙酮酸激酶的多种同工型在不同细胞类型中表达。其中一种同工型，即Tu M2-PK型，在肿瘤细胞中强烈过表达并释放到体液中。体液中Tu M2-PK的浓度可通过市售的酶联免疫吸附测定（ELISA）试剂盒进行定量测定。使用该试剂盒，测定了64例肾癌患者和10例肾炎患者的EDTA血浆中Tu M2-PK的浓度。两组的Tu M2-PK浓度范围没有重叠，表明肾癌与良性肾脏疾病有高度显著的区分。此外，64例患者的EDTA血浆中Tu M2-PK浓度与罗布森肿瘤分期密切相关。目前的结果表明，Tu M2-PK可能是第一个肿瘤标志物，可作为肾癌诊断程序的极佳补充。
